Insulet (PODD) Stock Price, News & Analysis

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PODD shares.
View PODD analyst ratings or view top-rated stocks.

15 equities research analysts have issued 12-month target prices for Insulet's stock. Their PODD share price targets range from $184.00 to $330.00. On average, they expect the company's share price to reach $243.21 in the next year. This suggests a possible upside of 46.3% from the stock's current price.
View analysts price targets for PODD or view top-rated stocks among Wall Street analysts.

Insulet's stock was trading at $216.98 on January 1st, 2024. Since then, PODD stock has decreased by 23.4% and is now trading at $166.25.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PODD earnings forecast.

Insulet will be holding an earnings conference call on Thursday, May 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Insulet Co. (NASDAQ:PODD) posted its earnings results on Thursday, February, 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.73. The medical instruments supplier had revenue of $509.80 million for the quarter, compared to analyst estimates of $461.26 million. Insulet had a trailing twelve-month return on equity of 32.19% and a net margin of 12.16%. The business's revenue for the quarter was up 37.9% on a year-over-year basis. During the same quarter last year, the business earned $0.55 EPS.

ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include Fidelity Digital Health ETF (FDHT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco Focused Discovery Growth ETF (IVDG), First Trust Indxx Medical Devices ETF (MDEV), Fidelity Disruptive Medicine ETF (FMED), Simplify Health Care ETF (PINK) and SPDR S&P Health Care Equipment ETF (XHE).

Insulet updated its first quarter 2024 earnings guidance on Thursday, February, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $419.0 million-$429.7 million, compared to the consensus revenue estimate of $442.5 million.

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

Insulet's stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.43%), Sumitomo Mitsui Trust Holdings Inc. (0.24%), Portman Square Capital LLP (0.00%), Congress Asset Management Co. MA (0.06%), Norden Group LLC (0.04%) and Banque Cantonale Vaudoise (0.01%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, James Hollingshead, John A Fallon, Luciana Borio, Michael P Spears, Prem Singh, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends.

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.